上海医药 - Financials

上海医药 — Financial Statements

Annual Quarterly

5 10 All

Income Statement

Balance Sheet

Cash Flow

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
+Revenue	275.3B	260.3B	232.0B	215.8B	191.9B
Revenue Growth %	5.7%	12.2%	7.5%	12.5%	--
Total Revenue	275.3B	260.3B	232.0B	215.8B	191.9B
Cost Of Revenue	244.6B	229.0B	201.5B	187.3B	165.2B
+Gross Profit	30.6B	31.3B	30.5B	28.5B	26.7B
Gross Margin %	11.1%	12.0%	13.1%	13.2%	13.9%
Total Operating Cost	268.5B	253.8B	225.6B	209.8B	186.4B
Selling Expenses	12.7B	13.9B	14.3B	13.3B	12.2B
Admin Expenses	5.7B	5.7B	5.0B	5.1B	4.7B
Rd Expenses	2.4B	2.2B	2.1B	2.0B	1.7B
Finance Expenses	1.5B	1.5B	1.3B	1.2B	1.2B
+Operating Income	8.1B	7.7B	9.0B	8.2B	7.2B
Operating Margin %	3.0%	2.9%	3.9%	3.8%	3.7%
Non Operating Income	156.0M	40.7M	32.8M	82.0M	193.0M
Non Operating Expenses	277.0M	654.0M	239.0M	144.0M	202.0M
Investment Income	380.0M	-68.1M	533.0M	1.8B	976.0M
Fair Value Change Income	204.0M	405.0M	219.0M	-206.0M	117.0M
Asset Disposal Income	188.0M	92.5M	1.4B	58.3M	52.1M
Asset Impairment Loss	614.0M	561.0M	331.0M	140.0M	899.0M
Other Income	634.0M	793.0M	394.0M	499.0M	549.0M
Income Before Tax	8.0B	7.1B	8.8B	8.1B	7.2B
Income Tax	2.1B	1.9B	1.8B	1.9B	1.6B
+Net Income	5.9B	5.2B	7.0B	6.3B	5.6B
Net Margin %	2.1%	2.0%	3.0%	2.9%	2.9%
Net Income Attributable	4.6B	3.8B	5.6B	5.1B	4.5B
Minority Interest	1.3B	1.4B	1.4B	1.2B	1.1B
Eps Basic	1.23	1.02	1.61	1.79	1.58
Eps Diluted	1.23	1.02	1.61	1.79	1.58

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash And Equivalents	35.7B	30.5B	27.4B	22.4B	22.3B
Trading Financial Assets	8.6B	10.2B	9.6B	--	--
Accounts Receivable	79.1B	72.9B	66.8B	58.1B	52.7B
Notes Receivable	1.1B	1.9B	1.8B	1.3B	291.0M
Notes And Accounts Receivable	80.3B	74.8B	68.6B	59.4B	53.0B
Prepayments	1.9B	3.2B	3.9B	2.5B	2.4B
Inventory	38.9B	36.6B	34.5B	27.1B	24.1B
Total Current Assets	171.8B	162.4B	149.5B	116.5B	107.6B
Long Term Equity Investment	8.1B	8.4B	9.2B	9.1B	6.7B
Fixed Assets	--	12.2B	11.5B	10.5B	10.5B
Fixed Assets Total	14.9B	12.2B	11.5B	10.5B	10.5B
Construction In Progress	--	3.6B	2.8B	2.9B	1.7B
Construction In Progress Total	2.1B	3.6B	2.8B	2.9B	1.7B
Intangible Assets	5.6B	6.1B	6.2B	6.0B	5.2B
Long Term Deferred Expenses	535.0M	475.0M	462.0M	429.0M	415.0M
Total Non Current Assets	49.4B	49.5B	48.6B	46.9B	41.6B
Total Assets	221.2B	212.0B	198.1B	163.4B	149.2B
Short Term Borrowings	38.1B	35.6B	27.8B	22.5B	20.1B
Accounts Payable	50.2B	47.9B	45.6B	37.2B	32.9B
Advance Receipts	--	--	--	--	--
Contract Liabilities	1.6B	2.0B	2.2B	1.3B	1.3B
Total Current Liabilities	126.0B	122.4B	110.7B	91.8B	88.1B
Long Term Borrowings	8.3B	5.8B	6.3B	7.2B	1.2B
Total Non Current Liabilities	11.4B	9.3B	9.4B	12.5B	6.3B
Total Liabilities	137.5B	131.6B	120.1B	104.4B	94.4B
Paid In Capital	3.7B	3.7B	3.7B	2.8B	2.8B
Capital Reserve	29.6B	29.2B	29.1B	16.1B	15.9B
Surplus Reserve	2.3B	2.3B	2.2B	2.0B	1.8B
Retained Earnings	36.5B	33.8B	32.5B	28.6B	25.1B
Minority Equity	12.1B	11.8B	10.9B	9.7B	9.4B
Equity Attributable	71.7B	68.5B	67.1B	49.4B	45.4B
Total Equity	83.7B	80.3B	78.0B	59.1B	54.7B

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash From Sales	301.1B	283.6B	249.9B	233.4B	210.0B
Tax Refunds Received	157.0M	114.0M	301.0M	114.0M	66.7M
Total Operating Cash Inflow	304.7B	286.8B	252.4B	235.5B	212.0B
Cash Paid For Goods	268.1B	252.0B	218.8B	203.7B	180.2B
Cash Paid To Employees	10.6B	9.9B	9.2B	8.7B	7.7B
Taxes Paid	7.3B	7.5B	7.9B	6.4B	5.9B
Total Operating Cash Outflow	298.8B	281.6B	247.7B	230.4B	205.1B
Operating Cash Flow	5.8B	5.2B	4.7B	5.1B	6.8B
Total Investing Cash Inflow	50.4B	29.3B	31.7B	5.1B	9.5B
Total Investing Cash Outflow	50.0B	31.8B	44.2B	11.1B	11.2B
Investing Cash Flow	416.0M	-2.5B	-12.5B	-6.0B	-1.7B
Cash From Borrowings	61.9B	64.2B	48.7B	37.6B	36.8B
Dividends And Interest Paid	4.3B	4.9B	3.8B	3.3B	3.5B
Debt Repayments	70.1B	72.3B	59.8B	52.2B	47.6B
Total Financing Cash Inflow	74.1B	79.7B	78.3B	58.3B	51.1B
Total Financing Cash Outflow	76.0B	79.5B	66.1B	56.8B	52.3B
Financing Cash Flow	-1.9B	232.0M	12.1B	1.6B	-1.3B
Net Change In Cash	4.4B	3.0B	4.4B	561.0M	3.9B
Ending Cash Balance	31.9B	27.5B	24.5B	20.1B	19.6B
Capex	2.4B	3.0B	2.7B	4.1B	3.0B